Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Auer, M; Bsteh, G; Hegen, H; Wurth, S; Zinganell, A; Berger, T; Deisenhammer, F; Pauli, FD.
Late-onset neutropenia in a multiple sclerosis patient after first dose ocrelizumab switched from rituximab.
Mult Scler Relat Disord. 2020; 43(8):102155-102155
Doi: 10.1016/j.msard.2020.102155
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Wurth Sebastian
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Ocrelizumab is a humanized monoclonal anti-CD20 antibody approved for treatment of relapsing-remitting and primary progressive multiple sclerosis (MS). Before approval of this drug, the chimeric anti-CD20 antibody rituximab was used off-label for treatment of MS. On treatment with rituximab late-onset neutropenia (LON) was reported as a rare adverse event. Here we report the case of a patient with MS who first received rituximab without experiencing any hematologic abnormalities, but developed grade IV LON after switching to ocrelizumab. This first case of LON in a patient treated with different anti-CD20 antibodies highlights the necessity of regular hemogram examinations during ocrelizumab. Copyright © 2020 Elsevier B.V. All rights reserved.
- Find related publications in this database (using NLM MeSH Indexing)
- Antibodies, Monoclonal, Humanized - adverse effects
- Humans -
- Immunologic Factors - adverse effects
- Multiple Sclerosis - drug therapy
- Neutropenia - chemically induced
- Rituximab - adverse effects
- Find related publications in this database (Keywords)
- Neutropenia
- Adverse event
- Multiple sclerosis
- Ocrelizumab
- Rituximab
- Treatment